New drug aims to shield cancer patients from Chemo's hidden damage
NCT ID NCT05256745
Summary
This early-stage study is testing if a drug called azeliragon can protect women's hearts and thinking skills during chemotherapy for early breast cancer. Researchers want to see if adding azeliragon to standard chemo is safe and can reduce heart damage and 'chemo brain.' The trial will enroll 48 women who are about to start specific chemotherapy regimens.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medstar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.